AI Algorithm Matches Pathologists in Diagnosing Celiac Disease, Study Finds

AI is as good as pathologists at diagnosing Celiac disease, study finds

A machine learning algorithm developed by Cambridge scientists was able to correctly identify in 97 cases out of 100 whether or not an individual had coeliac disease based on their biopsy, new research has shown. The AI tool, which has been trained on almost 3,400 scanned biopsies from four NHS hospitals, could speed up diagnosis of the condition and take pressure off stretched healthcare resources, as well as improving diagnosis in developing nations, where shortages of pathologists are severe. Digital tools that can speed up or even automate analysis of diagnostic tests are beginning to show real promise for reducing the demands on pathologists. A large amount of this work has focused on the detection of cancer, but researchers are beginning to look at opportunities to diagnose other types of disease. One condition being looked at by scientists at the University of Cambridge is coeliac disease, an autoimmune disease trigged by consuming gluten. It causes symptoms that include stomach cramps, diarrhoea, skin rashes, weight loss, fatigue and anaemia. Because symptoms vary so much between individuals, patients often have difficulty in receiving an accurate diagnosis. The gold standard for diagnosing coeliac disease is via a biopsy of the duodenum (part of the small intestine). Pathologists will then analyse the sample under a microscope or on a computer to look for damage to the villi, tiny hair-like projections that line the inside of the small intestine. Interpreting biopsies, which often have subtle changes, can be subjective. Pathologists use a classification system known as the Marsh-Oberhuber scale to judge the severity of a case, ranging from zero (the villi are normal and the patient is unlikely to have the disease) to four (the villi are completely flattened). In research published today in the New England Journal of Medicine AI, Cambridge researchers developed a machine learning algorithm to classify biopsy image data. The algorithm was trained and tested on a large-scale, diverse dataset consisting of over 4,000 images obtained from five different hospitals using five different scanners from four different companies. Senior author Professor Elizabeth Soilleux from the Department of Pathology and Churchill College, University of Cambridge, said: "Coeliac disease affects as many as one in 100 people and can cause serious illness, but getting a diagnosis is not straightforward. It can take many years to receive an accurate diagnosis, and at a time of intense pressures on healthcare systems, these delays are likely to continue. AI has the potential to speed up this process, allowing patients to receive a diagnosis faster, while at the same time taking pressure off NHS waiting lists." The team tested their algorithm on an independent data set of almost 650 images from a previously unseen source. Based on comparisons with the original pathologists' diagnoses, the researchers showed that the model was correct in its diagnosis in more than 97 cases out of 100. The model had a sensitivity of over 95% -- meaning that it correctly identified more than 95 cases out of 100 individuals who had coeliac disease. It also had a specificity of almost 98% -- meaning that it correctly identified in nearly 98 cases out of 100 individuals who did not have coeliac disease. Previous research by the team has shown that even pathologists can disagree on diagnoses. When shown a series of 100 slides and asked to diagnose whether a patient had coeliac disease, did not have the disease, or whether the diagnosis was indeterminate, the team showed that there was disagreement in more than one in five cases. This time round, the researchers asked four pathologists to review 30 slides and found that a pathologist was as likely to agree with the AI model as they were with a second pathologist. Dr Florian Jaeckle, also from the Department of Pathology, and a Research Fellow at Hughes Hall, Cambridge, said: "This is the first time AI has been shown to diagnose as accurately as an experienced pathologist whether an individual has coeliac or not. Because we trained it on data sets generated under a number of different conditions, we know that it should be able to work in a wide range of settings, where biopsies are processed and imaged differently. "This is an important step towards speeding up diagnoses and freeing up pathologists' time to focus on more complex or urgent cases. Our next step is to test the algorithm in a much larger clinical sample, putting us in a position to share this device with the regulator, bringing us nearer to this tool being used in the NHS." The researchers have been working with patient groups, including through Coeliac UK, to share their approach and discuss with them their receptiveness to technology such as this being used. "When we speak to patients, they are generally very receptive to the use of AI for diagnosing coeliac disease," added Dr Jaeckle. "This no doubt partly reflects their experiences of the difficulties and delays in receiving a diagnosis. "One issue that comes up frequently with both patients and clinicians is the issue of 'explainability' -- being able to understand and explain how AI reaches its diagnosis. It's important for us as researchers and for regulators to bear this mind if we want to ensure there is public trust in applications of AI in medicine." Professor Soilleux is a consultant haematopathologist at Cambridge University Hospitals NHS Foundation Trust. Together with Dr Jaeckle, she has set up a spinout company, Lyzeum Ltd, to commercialise the algorithm. The research was funded by Coeliac UK, Innovate UK, the Cambridge Centre for Data-Driven Discovery and the National Institute for Health and Care Research. Keira Shepherd, Research Officer at Coeliac UK, said: "During the diagnostic process, it's vital that patients keep gluten in their diet to ensure that the diagnosis is accurate. But this can cause uncomfortable symptoms. That's why it's really important that they are able to receive an accurate diagnosis as quickly as possible. "This research demonstrates one potential way to speed up part of the diagnosis journey. At Coeliac UK, we're proud to have funded the early stages of this work, which initially focused on training a system to differentiate between healthy control biopsies and biopsies of patients with coeliac disease. We hope that one day this technology will be used to help patients receive a quick and accurate diagnosis."

AI matches pathologists in diagnosing celiac disease

University of CambridgeMar 27 2025 A machine learning algorithm developed by Cambridge scientists was able to correctly identify in 97 cases out of 100 whether or not an individual had celiac disease based on their biopsy, new research has shown. The AI tool, which has been trained on almost 3,400 scanned biopsies from four NHS hospitals, could speed up diagnosis of the condition and take pressure off stretched healthcare resources, as well as improving diagnosis in developing nations, where shortages of pathologists are severe. Digital tools that can speed up or even automate analysis of diagnostic tests are beginning to show real promise for reducing the demands on pathologists. A large amount of this work has focused on the detection of cancer, but researchers are beginning to look at opportunities to diagnose other types of disease. One condition being looked at by scientists at the University of Cambridge is celiac disease, an autoimmune disease trigged by consuming gluten. It causes symptoms that include stomach cramps, diarrhoea, skin rashes, weight loss, fatigue and anaemia. Because symptoms vary so much between individuals, patients often have difficulty in receiving an accurate diagnosis. The gold standard for diagnosing celiac disease is via a biopsy of the duodenum (part of the small intestine). Pathologists will then analyse the sample under a microscope or on a computer to look for damage to the villi, tiny hair-like projections that line the inside of the small intestine. Interpreting biopsies, which often have subtle changes, can be subjective. Pathologists use a classification system known as the Marsh-Oberhuber scale to judge the severity of a case, ranging from zero (the villi are normal and the patient is unlikely to have the disease) to four (the villi are completely flattened). In research published today in the New England Journal of Medicine AI, Cambridge researchers developed a machine learning algorithm to classify biopsy image data. The algorithm was trained and tested on a large-scale, diverse dataset consisting of over 4,000 images obtained from five different hospitals using five different scanners from four different companies. Celiac disease affects as many as one in 100 people and can cause serious illness, but getting a diagnosis is not straightforward. It can take many years to receive an accurate diagnosis, and at a time of intense pressures on healthcare systems, these delays are likely to continue. AI has the potential to speed up this process, allowing patients to receive a diagnosis faster, while at the same time taking pressure off NHS waiting lists." Elizabeth Soilleux, Senior Author, Professor, Department of Pathology and Churchill College, University of Cambridge The team tested their algorithm on an independent data set of almost 650 images from a previously unseen source. Based on comparisons with the original pathologists' diagnoses, the researchers showed that the model was correct in its diagnosis in more than 97 cases out of 100. The model had a sensitivity of over 95% - meaning that it correctly identified more than 95 cases out of 100 individuals who had celiac disease. It also had a specificity of almost 98% - meaning that it correctly identified in nearly 98 cases out of 100 individuals who did not have celiac disease. Previous research by the team has shown that even pathologists can disagree on diagnoses. When shown a series of 100 slides and asked to diagnose whether a patient had celiac disease, did not have the disease, or whether the diagnosis was indeterminate, the team showed that there was disagreement in more than one in five cases. This time round, the researchers asked four pathologists to review 30 slides and found that a pathologist was as likely to agree with the AI model as they were with a second pathologist. Dr Florian Jaeckle, also from the Department of Pathology, and a Research Fellow at Hughes Hall, Cambridge, said: "This is the first time AI has been shown to diagnose as accurately as an experienced pathologist whether an individual has celiac or not. Because we trained it on data sets generated under a number of different conditions, we know that it should be able to work in a wide range of settings, where biopsies are processed and imaged differently. "This is an important step towards speeding up diagnoses and freeing up pathologists' time to focus on more complex or urgent cases. Our next step is to test the algorithm in a much larger clinical sample, putting us in a position to share this device with the regulator, bringing us nearer to this tool being used in the NHS." The researchers have been working with patient groups, including through celiac UK, to share their approach and discuss with them their receptiveness to technology such as this being used. "When we speak to patients, they are generally very receptive to the use of AI for diagnosing celiac disease," added Dr Jaeckle. "This no doubt partly reflects their experiences of the difficulties and delays in receiving a diagnosis. "One issue that comes up frequently with both patients and clinicians is the issue of 'explainability' - being able to understand and explain how AI reaches its diagnosis. It's important for us as researchers and for regulators to bear this mind if we want to ensure there is public trust in applications of AI in medicine." Professor Soilleux is a consultant haematopathologist at Cambridge University Hospitals NHS Foundation Trust. Together with Dr Jaeckle, she has set up a spinout company, Lyzeum Ltd, to commercialise the algorithm. The research was funded by celiac UK, Innovate UK, the Cambridge Centre for Data-Driven Discovery and the National Institute for Health and Care Research. Keira Shepherd, Research Officer at celiac UK, said: "During the diagnostic process, it's vital that patients keep gluten in their diet to ensure that the diagnosis is accurate. But this can cause uncomfortable symptoms. That's why it's really important that they are able to receive an accurate diagnosis as quickly as possible. "This research demonstrates one potential way to speed up part of the diagnosis journey. At celiac UK, we're proud to have funded the early stages of this work, which initially focused on training a system to differentiate between healthy control biopsies and biopsies of patients with celiac disease. We hope that one day this technology will be used to help patients receive a quick and accurate diagnosis." "Anything that makes the system quicker must be a good thing" - Liz Cox, 80 Liz Cox, 80, had been having symptoms including anaemia and stomach pains for almost 30 years when a question from a friend - "Are you still losing weight?" - made her realise that she ought to seek help. Born in Tottenham, North London, towards the end of the Second World War, Liz has moved around, spending part of her life in Singapore after getting married before settling down to live in Linton, just outside Cambridge. She had spent most of her life working in libraries and took up a "retirement job" working in Linton's community library. Liz began with severe stomach pains in her 30s, after having her three children. "My doctor carried out various tests, but celiac disease wasn't very well known then, so I wasn't tested for that. I was quite tired, but I just carried on because you have to when you've got three children and a husband, don't you?" Liz tried not to let her condition get in the way, making sure she found time for activities she enjoyed, such as skiing and dancing, and it wasn't until her late 50s, prompted by her friend's question, that she went back to the doctor. This time, her GP in Linton did a blood test, which suggested advanced celiac disease. A biopsy at Addenbrooke's Hospital confirmed this - but also found pre-cancerous cells. "I used to see Dr Jeremy Woodward, my consultant, every year for an endoscopy. Wasn't I lucky!" she says. After about 10 years, she was given the all-clear for cancer and discharged. Since her diagnosis, Liz has been on a strict, gluten-free diet, which had an effect almost immediately. She isn't tempted to have even the smallest amount of gluten now. "Some people say, 'Have a little bit', but no, it's a strict diet, because you don't know what it's doing to your insides. It's just mind over matter, isn't it? You can't have it, end of story." She joined a celiac UK support group in Bury St Edmunds, which helped her meet others like herself, share tips and find good places to eat that did gluten-free options. She was talked into becoming the Secretary, with her husband agreeing to become Membership Secretary - they have been doing this now for 20 years. It was through this group that Liz met Professor Elizabeth Soilleux from the University of Cambridge. "Elizabeth came to our meeting to talk about her research. It was quite fun because she showed us pictures of biopsies and said could we guess which were celiac and which weren't? It wasn't easy." Liz is impressed with the use of AI to diagnose celiac disease. Her referral for an endoscopy and the subsequent diagnosis happened relatively quickly. Not everyone is as fortunate. "You hear stories from other people, and they've waited a long time. They go back and forward to the doctor's often, with various odd symptoms, and perhaps the doctors don't always test them for that. "Anything that makes the system quicker must be a good thing, because once you've been diagnosed and you know you can't have gluten, then you know what to do, and you feel so much better." University of Cambridge Journal reference: Jaeckle, F., et al. (2025). Machine Learning Achieves Pathologist-Level Celiac Disease Diagnosis. NEJM AI. doi.org/10.1056/aioa2400738.

AI is as good as pathologists at diagnosing celiac disease, study finds

A machine learning algorithm developed by Cambridge scientists was able to correctly identify in 97 cases out of 100 whether or not an individual had celiac disease based on their biopsy, new research has shown. The AI tool, which has been trained on almost 3,400 scanned biopsies from four NHS hospitals, could speed up diagnosis of the condition and take pressure off stretched health care resources, as well as improve diagnosis in developing nations, where shortages of pathologists are severe. Digital tools that can speed up or even automate analysis of diagnostic tests are beginning to show real promise for reducing the demands on pathologists. A large amount of this work has focused on the detection of cancer, but researchers are beginning to look at opportunities to diagnose other types of disease. One condition being looked at by scientists at the University of Cambridge is celiac disease, an autoimmune disease triggered by consuming gluten. It causes symptoms that include stomach cramps, diarrhea, skin rashes, weight loss, fatigue and anemia. Because symptoms vary so much between individuals, patients often have difficulty in receiving an accurate diagnosis. The gold standard for diagnosing celiac disease is via a biopsy of the duodenum (part of the small intestine). Pathologists will then analyze the sample under a microscope or on a computer to look for damage to the villi, tiny hair-like projections that line the inside of the small intestine. Interpreting biopsies, which often have subtle changes, can be subjective. Pathologists use a classification system known as the Marsh-Oberhuber scale to judge the severity of a case, ranging from zero (the villi are normal and the patient is unlikely to have the disease) to four (the villi are completely flattened). In research published in the NEJM AI, Cambridge researchers developed a machine learning algorithm to classify biopsy image data. The algorithm was trained and tested on a large-scale, diverse dataset consisting of over 4,000 images obtained from five different hospitals using five different scanners from four different companies. Senior author Professor Elizabeth Soilleux from the Department of Pathology and Churchill College, University of Cambridge, said, "Celiac disease affects as many as one in 100 people and can cause serious illness, but getting a diagnosis is not straightforward. "It can take many years to receive an accurate diagnosis, and at a time of intense pressures on health care systems, these delays are likely to continue. AI has the potential to speed up this process, allowing patients to receive a diagnosis faster, while at the same time taking pressure off NHS waiting lists." The team tested their algorithm on an independent data set of almost 650 images from a previously unseen source. Based on comparisons with the original pathologists' diagnoses, the researchers showed that the model was correct in its diagnosis in more than 97 cases out of 100. The model had a sensitivity of over 95% -- meaning that it correctly identified more than 95 cases out of 100 individuals who had celiac disease. It also had a specificity of almost 98% -- meaning that it correctly identified in nearly 98 cases out of 100 individuals who did not have celiac disease. Previous research by the team has shown that even pathologists can disagree on diagnoses. When shown a series of 100 slides and asked to diagnose whether a patient had celiac disease, did not have the disease, or whether the diagnosis was indeterminate, the team showed that there was disagreement in more than one in five cases. This time round, the researchers asked four pathologists to review 30 slides and found that a pathologist was as likely to agree with the AI model as they were with a second pathologist. Dr. Florian Jaeckle, also from the Department of Pathology, and a Research Fellow at Hughes Hall, Cambridge, said, "This is the first time AI has been shown to diagnose as accurately as an experienced pathologist whether an individual has celiac or not. "Because we trained it on data sets generated under a number of different conditions, we know that it should be able to work in a wide range of settings, where biopsies are processed and imaged differently. "This is an important step towards speeding up diagnoses and freeing up pathologists' time to focus on more complex or urgent cases. Our next step is to test the algorithm in a much larger clinical sample, putting us in a position to share this device with the regulator, bringing us nearer to this tool being used in the NHS." The researchers have been working with patient groups, including through Celiac UK, to share their approach and discuss with them their receptiveness to technology such as this being used. "When we speak to patients, they are generally very receptive to the use of AI for diagnosing celiac disease," added Dr. Jaeckle. "This no doubt partly reflects their experiences of the difficulties and delays in receiving a diagnosis. "One issue that comes up frequently with both patients and clinicians is the issue of 'explainability' -- being able to understand and explain how AI reaches its diagnosis. It's important for us as researchers and for regulators to bear this in mind if we want to ensure there is public trust in applications of AI in medicine." Professor Soilleux is a consultant hematopathologist at Cambridge University Hospitals NHS Foundation Trust. Together with Dr. Jaeckle, she has set up a spinout company, Lyzeum Ltd, to commercialize the algorithm. Keira Shepherd, Research Officer at Celiac UK, said, "During the diagnostic process, it's vital that patients keep gluten in their diet to ensure that the diagnosis is accurate. But this can cause uncomfortable symptoms. That's why it's really important that they are able to receive an accurate diagnosis as quickly as possible. "This research demonstrates one potential way to speed up part of the diagnosis journey ... we hope that one day this technology will be used to help patients receive a quick and accurate diagnosis."

Researchers develop AI tool that could speed up coeliac disease diagnosis

Cambridge study finds algorithm is as effective as a pathologist in detecting disease - and much quicker AI could speed up the diagnosis of coeliac disease, according to research. Coeliac disease is an autoimmune condition affecting just under 700,000 people in the UK, but getting an accurate diagnosis can take years. It is caused by consuming gluten - found in wheat, rye and barley - and symptoms include stomach cramps, diarrhoea, skin rashes, weight loss, fatigue and anaemia. Untreated coeliac disease can lead to more serious complications such as malnutrition, osteoporosis, anaemia and infertility, as well as an increased risk of certain cancers and other autoimmune conditions. At present, most adults are diagnosed through a blood test for the presence of antibodies to gluten, followed by a biopsy of the duodenum. Pathologists then check the biopsy sample for damage to the villi, tiny hair-like projections lining the small intestine that enable the absorption of nutrients. Now scientists at the University of Cambridge have developed an AI tool that could speed up diagnosis rates and free up pathologists' time for more complex cases. The algorithm was trained and tested on more than 4,000 images obtained from five different hospitals, using five different scanners from four different companies. The study, published in the New England Journal of Medicine AI, found that the algorithm was as effective as a pathologist in diagnosing coeliac disease. And crucially, the machine-learning algorithm was substantially faster compared with a pathologist. Elizabeth Soilleux, a consultant haematopathologist and professor of pathology at the University of Cambridge, a senior author of the research, said: "It can take many years to receive an accurate diagnosis, and at a time of intense pressures on healthcare systems, these delays are likely to continue. AI has the potential to speed up this process, allowing patients to receive a diagnosis faster, while at the same time taking pressure off NHS waiting lists." According to Dr Florian Jaeckle, a co-author of the research, it takes a pathologist five to 10 minutes to to analyse each biopsy, whereas the AI model can diagnose coeliac disease straight away. "Duodenal biopsies (and in particular tests for coeliac disease) are often put at the back of the pathologist's lists as they are not as serious as for example a possible cancer case, meaning that patients often have to wait weeks or even months to find out if they have coeliac disease," he said. "With AI they could get a result almost instantly, because it is able to generate results in less than a minute and as soon as a biopsy is scanned. Therefore, there would never be a waiting list with AI." The study was funded by Coeliac UK, Innovate UK, the Cambridge Centre for Data-Driven Discovery and the National Institute for Health and Care Research. Responding to the findings, Dr Bernie Croal, the president of the Royal College of Pathologists, said the new AI tool, "has the potential to radically transform how we diagnose coeliac disease, benefiting patients by speeding up diagnosis, improving health outcomes and shortening waiting lists". "While the advent of AI in pathology is very exciting, and the NHS could be a world leader in the development and use of AI in pathology, more work will be needed to get to the point where AI is fully developed and used safely in the NHS. Investment in digital pathology, joined up functional IT systems, which facilitate information sharing across organisations, as well as training for pathologists to understand and use AI, will all need to be put in place."

AI Improves Diagnosis Of Celiac Disease

FRIDAY, March 28, 2025 (HealthDay News) -- Liz Cox, 80, had been suffering from severe stomach pains and anemia for nearly 30 years before doctors finally diagnosed her with celiac disease. Cox first developed severe stomach pains in her 30s, after having her three children. "My doctor carried out various tests, but celiac disease wasn't very well known then, so I wasn't tested for that," Cox, who lives in Linton, England, recalls. "I was quite tired, but I just carried on because you have to when you've got three children and a husband, don't you?" Now, a new artificial intelligence-driven breakthrough might be able to prevent others from suffering in silence as Cox did, researchers said. An AI program correctly identified in 97 out of 100 cases whether a person had celiac disease based on biopsy results, researchers reported March 27 in the New England Journal of Medicine AI. The AI could speed up diagnosis of celiac disease, researchers said. "Celiac disease affects as many as 1 in 100 people and can cause serious illness, but getting a diagnosis is not straightforward," senior researcher Elizabeth Soilleux, a professor of pathology at the University of Cambridge in the U.K., said in a news release. "It can take many years to receive an accurate diagnosis, and at a time of intense pressures on healthcare systems, these delays are likely to continue," Soilleux continued. "AI has the potential to speed up this process, allowing patients to receive a diagnosis faster." Celiac disease is an autoimmune disorder in which eating gluten causes the immune system to turn on the digestive system, leading to damage in the small intestine. Symptoms can include stomach cramps, diarrhea, skin rashes, weight loss, fatigue and anemia, researchers said. Only about 30% of people with celiac disease are properly diagnosed, according to the Celiac Disease Foundation. The gold standard for diagnosing celiac disease is through a biopsy of the duodenum, which is part of the small intestine, researchers said. Pathologists examine biopsy samples under a microscope to look for damage to the villi, the tiny finger-like projections that line the inside of the small intestine and absorb nutrients from digested food. However, it can be tough for pathologists to properly judge these biopsies, which might feature very subtle changes in a person's villi. Previous studies have found that pathologists disagree on celiac disease diagnoses in more than 1 in 5 cases. To try and improve diagnosis, researchers trained a new AI tool on nearly 3,400 biopsies from hospitals in the U.K.'s National Health Service, including more than 4,000 images captured from those biopsies. The team then tested the AI on another set of nearly 650 biopsy images. The AI correctly identified more than 95 cases out of 100 people who'd been diagnosed with celiac disease, results show. It also correctly ruled out celiac disease in nearly 98 of 100 cases among people who didn't have the disorder. Pathologists asked to look at the same images were as likely to agree with the AI model as they were with a second pathologist, the study found. "This is the first time AI has been shown to diagnose as accurately as an experienced pathologist whether an individual has celiac or not," lead investigator Florian Jaeckle, a research fellow at the University of Cambridge, said in a news release. "Because we trained it on data sets generated under a number of different conditions, we know that it should be able to work in a wide range of settings, where biopsies are processed and imaged differently," he added. Researchers next plan to test the AI in a much larger group of patients before submitting it to review by regulators. In Cox's case, a strict gluten-free diet improved her symptoms almost immediately. "Some people say, 'Have a little bit', but no, it's a strict diet, because you don't know what it's doing to your insides," Cox said. "It's just mind over matter, isn't it? You can't have it, end of story." Cox is impressed with the new AI program developed at Cambridge, and hopes it will help others get a diagnosis more quickly than she did. "You hear stories from other people, and they've waited a long time. They go back and forward to the doctor's often, with various odd symptoms, and perhaps the doctors don't always test them for that," she said. "Anything that makes the system quicker must be a good thing, because once you've been diagnosed and you know you can't have gluten, then you know what to do, and you feel so much better," Cox concluded. SOURCE: University of Cambridge, news release, March 27, 2025